NCT02117362: Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma |
|
|
| Completed | 1 | 8 | US | 1 mg/kg GR-MD-02, galectin-3 inhibitor, galactoarabino-rhamnogalacturonate, 2 mg/kg GR-MD-02, 4 mg/kg GR-MD-02, 8 mg/kg GR-MD-02, Ipilimumab, Yervoy, Anti-CTLA 4 | Providence Health & Services, Providence Cancer Center, Earle A. Chiles Research Institute, Galectin Therapeutics Inc. | Metastatic Melanoma | 11/18 | 11/18 | | |
